AN2 Therapeutics (ANTX) Total Non-Current Liabilities (2024 - 2026)

AN2 Therapeutics (ANTX) has 3 years of Total Non-Current Liabilities data on file, last reported at $5.6 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8.7 million, down 14.83% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $5.6 million, down from $8.7 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ANTX reached as high as $10.2 million in Q4 2024 and fell as low as $5.6 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $8.2 million across 3 years, with a median of $8.7 million in 2025.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 14.83% in 2025 and fell as far as 14.83% in 2025.
• Year by year, Total Non-Current Liabilities stood at $10.2 million in 2024, then decreased by 14.83% to $8.7 million in 2025, then plunged by 36.22% to $5.6 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $10.2 million in Q4 2024.